In the fourth quarter of 2024, BB Biotech shares posted a total return of -2.7% in CHF and -3.5% in EUR. NAV performance improved, rising by 2.7% in CHF and 2.8% in EUR, though it declined by 4.3% in ...

Back when NAV was something that guided you to your chosen venue for the evening, the FFA conference in Miami (and earlier still, New York) was ...

2025 is shaping up to be a year of renewed momentum in real estate: despite elevated mortgage rates and home prices, demand ...

Safehold Inc. (NYSE:SAFE), the pioneering ground lease-focused real estate investment trust (REIT), continues to navigate a ...

The Simplify Volatility Premium ETF exemplifies an innovative approach to volatility harvesting, aiming to generate ...

Q3 2025 Management View CEO Ujjaval Desai reported strong results for the third fiscal quarter, with net investment income (NII) of $12.5 million, or $0.62 per share, and net realized gains of $0.10 ...

For example, consider that DSU traded briefly at a more than 30% discount to NAV during the 2020 COVID-induced market sell-off. Given these dynamics, I believe a modest discount to NAV is ...